GoodRx rallies as Raymond James upgrades following inaugural investor day

** Shares of GoodRx GDRX up 11.7% at $8.12 on Thurs as Raymond James upgrades to "outperform" from "market perform" in wake of digital healthcare platform's first investor day since its 2020 IPO

** GDRX shares tracking biggest daily pct gain since Feb 28, hit over 2-mth high

** Raymond James sets PT at $10, implying ~38% upside to GDRX shares last close

** Following investor day event on Weds, RJ analyst John Ransom points to co's reaccelerating rev, improving margins and more focused strategy

** Ransom says while he has been skeptical of GDRX over the past 2 years, the new management team has brought renewed focus to the business that prioritizes creating a "symbiotic relationship" with its retail network, which has stabilized "far better" than previously anticipated

** GDRX's stock on Weds rose 9% after co said it's targeting over $1 bln of rev and at least 35% EBITDA margin in 2026

** Co on Weds also announced new direct prescription contracting agreement with supermarket chain Kroger KR

** KeyBanc analyst Scott Schoenhaus reiterated "overweight" rating, saying in note late Weds that rev guidance was ~7% above consensus of ~$935 mln

** Schoenhaus said he came away more positive given "further clarity on some of the more dynamic industry challenges and company-specific strategies" in both its prescription transaction and manufacturing solutions businesses

** 11 of 20 analysts rate GDRX "strong buy" or "buy", 8 rate "hold" while 1 has "sell", per LSEG data, with median PT of $8.63

** With move on the session, shares up 21% YTD and up more than 50% in past six months